- Home
- CANF vs TRUG Comparison
CANF vs TRUG Comparison
Compare CANF & TRUG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CANF
- TRUG
- Stock Information
- Founded
- CANF 1994
- TRUG 1983
- Country
- CANF Israel
- TRUG United States
- Employees
- CANF N/A
- TRUG N/A
- Industry
- CANF Biotechnology: Pharmaceutical Preparations
- TRUG
- Sector
- CANF Health Care
- TRUG
- Exchange
- CANF Nasdaq
- TRUG NYSE
- Market Cap
- CANF 14.4M
- TRUG 12.7M
- IPO Year
- CANF N/A
- TRUG N/A
- Fundamental
- Price
- CANF $2.46
- TRUG $0.94
- Analyst Decision
- CANF Strong Buy
- TRUG
- Analyst Count
- CANF 2
- TRUG 0
- Target Price
- CANF $14.00
- TRUG N/A
- AVG Volume (30 Days)
- CANF 135.4K
- TRUG 16.8K
- Earning Date
- CANF 11-15-2024
- TRUG 10-22-2024
- Dividend Yield
- CANF N/A
- TRUG N/A
- EPS Growth
- CANF N/A
- TRUG N/A
- EPS
- CANF N/A
- TRUG N/A
- Revenue
- CANF $667,000.00
- TRUG $19,112,071.00
- Revenue This Year
- CANF $356.93
- TRUG N/A
- Revenue Next Year
- CANF N/A
- TRUG N/A
- P/E Ratio
- CANF N/A
- TRUG N/A
- Revenue Growth
- CANF N/A
- TRUG N/A
- 52 Week Low
- CANF $1.81
- TRUG $0.79
- 52 Week High
- CANF $4.69
- TRUG $11.82
- Technical
- Relative Strength Index (RSI)
- CANF 62.91
- TRUG 42.79
- Support Level
- CANF $1.87
- TRUG $0.79
- Resistance Level
- CANF $2.55
- TRUG $1.00
- Average True Range (ATR)
- CANF 0.17
- TRUG 0.09
- MACD
- CANF 0.06
- TRUG 0.00
- Stochastic Oscillator
- CANF 85.94
- TRUG 52.86
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).
About TRUG TRUGOLF HOLDINGS INC
TruGolf Holdings Inc is a indoor golf gaming solutions company. It has built video games ("Links"), innovative hardware solutions, and an all-new e-sports platform to connect golfers around the world with E6 CONNECT.